Vedolizumab has no effect on the course of non-alcoholic fatty liver disease: A retrospective cohort analysis
| Autor: | Prabhat Kumar, Ashraf Almomani, Somtochukwu Onwuzo, Antoine Boustany, Eduard Krishtopaytis, Dana Alshaikh, Almaza Albakri, Motasem Alkhayyat, Tareq Kiwan, Imad Asaad |
|---|---|
| Rok vydání: | 2023 |
| Předmět: |
Pharmacology
Ecology Physics and Astronomy (miscellaneous) Physiology General Chemical Engineering Organic Chemistry Biomedical Engineering Pharmaceutical Science General Physics and Astronomy Plant Science General Chemistry Condensed Matter Physics Biochemistry Analytical Chemistry Surfaces Coatings and Films Complementary and alternative medicine Nuclear Energy and Engineering Drug Discovery Molecular Medicine Agronomy and Crop Science Ecology Evolution Behavior and Systematics |
| Zdroj: | Journal of Clinical and Experimental Gastroenterology. 2:14-18 |
| DOI: | 10.46439/gastro.2.013 |
| Popis: | Background and Aim: Non-Alcoholic Fatty Liver Disease (NAFLD) is the commonest cause of chronic liver disease and is a leading cause of liver transplantation in the United States, with no approved medication to halt or reverse its progression. Recent animal-model prospective trial-suggested that drug Vedolizumab leads to improvement and reversal in the NAFLD-related metabolic derangements. Vedolizumab is an α4β7 integrin-inhibitor that is approved for use in IBD patients. Our study aims to understand Vedolizumab's impact on the course of NAFLD in inflammatory bowel disease (IBD) patients. Methods: We conducted a retrospective cohort analysis of 158 subjects with NAFLD who received Vedolizumab at Cleveland Clinic Foundation (CCF). One cohort of 79 patients with NAFLD who received Vedolizumab were matched with control group of 79 patients. We determined the primary outcome as the response to Vedolizumab measured as Fibrosis-4 (Fib-4) regression to |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|